Soleno Therapeutics, Inc. (SLNO) — Financial statements
Income statement, balance sheet, and cash flow for Soleno Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 190 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 3 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 188 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 41↓48.3% | 79↑211.9% | 25↑65.0% | 15↓28.8% | 21 | |
| General & Administrative Expenses | 0.00↓100.0% | 106↑685.3% | 13↑36.9% | 10↓8.9% | 11 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 132↑24.8% | 106↑685.3% | 13↑36.9% | 10↓8.9% | 11 | |
| Other Expenses | 0.00↓100.0% | 3↑19.5% | 3↑481.2% | -0.71↑2.6% | -0.73 | |
| Operating Expenses | 173↓7.9% | 188↑353.5% | 41↑69.6% | 24↓22.6% | 32 | |
| Total Costs & Expenses | 175↓6.5% | 188↑353.5% | 41↑69.6% | 24↓22.6% | 32 | |
| Operating Results | ||||||
| Operating Income | 15↑108.0% | -188↓353.5% | -41↓69.6% | -24↑22.6% | -32 | |
| Depreciation & Amortization | 2↑1.5% | 2↑1.5% | 2↓0.3% | 2↑0.1% | 2 | |
| EBITDA | 28↑116.3% | -174↓368.9% | -37↓67.5% | -22↑27.0% | -30 | |
| EBIT | 26↑115.0% | -176↓350.4% | -39↓62.0% | -24↑25.4% | -32 | |
| Interest & Other Income | ||||||
| Net Interest Income | 11↓2.9% | 12↑358.5% | 3↑759.3% | 0.30↑172.7% | 0.11 | |
| Interest Income | 17↑40.7% | 12↑367.5% | 3↑759.3% | 0.30↑172.7% | 0.11 | |
| Interest Expense | 5↑2270.6% | 0.23 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | -11↑5.3% | -12↓403.0% | -2↓626.1% | -0.33↓145.1% | 0.73 | |
| Other Income / Expenses | 6↓49.8% | 12↑393.4% | 2↑626.1% | 0.33↓46.6% | 0.62 | |
| Income Before Tax | 21↑111.9% | -176↓351.0% | -39↓62.0% | -24↑22.1% | -31 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | 21↑111.9% | -176↓351.0% | -39↓62.0% | -24↑22.1% | -31 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | 21↑111.9% | -176↓351.0% | -39↓62.0% | -24↑22.1% | -31 | |
| Bottom-Line Net Income | 20↑111.6% | -176↓351.0% | -39↓62.0% | -24↑22.1% | -31 | |
| EPS (Basic) | 0.41↑109.4% | -4.38↓85.6% | -2.36↑17.8% | -2.87↑50.6% | -5.81 | |
| EPS (Diluted) | 0.39↑108.9% | -4.38↓85.6% | -2.36↑17.8% | -2.87↑50.6% | -5.81 | |
| Weighted Average Shares | 53↑32.4% | 40↑143.6% | 16↑96.4% | 8↑57.9% | 5 | |
| Weighted Average Diluted Shares | 54↑35.2% | 40↑143.6% | 16↑96.4% | 8↑57.9% | 5 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.